• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCoronavirus

Fauci says he experienced ‘Paxlovid rebound’ but says the drug stopped his infection from becoming more severe

By
Erin Prater
Erin Prater
Down Arrow Button Icon
By
Erin Prater
Erin Prater
Down Arrow Button Icon
June 29, 2022, 4:09 PM ET
Updated June 29, 2022, 10:10 PM ET
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, attends a COVID federal response hearing on Capitol Hill on June 16.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, attends a COVID federal response hearing on Capitol Hill on June 16. Joe Raedle—Getty Images

Chief presidential medical adviser Dr. Anthony Fauci said this week that he experienced a so-called Paxlovid rebound after he took the antiviral to aid his recovery from COVID, but later clarified that the drug was important to his recovery. 

The symptoms he developed after he took the pill were more severe than those he had initially, he said.

“After I finished the five days of Paxlovid, I reverted to negative on an antigen test for three days in a row,” Fauci, 81, said during an event at Foreign Policy’s Global Health Forum, Bloomberg reported. “And then on the fourth day, just to be absolutely certain, I tested myself again.”

“I reverted back to positive,” he said. 

He then began a second course of Paxlovid when symptoms emerged “much worse than the first go-around,” he said. Fauci said he was feeling “reasonably good” as of Tuesday.

However, Fauci later told the New York Times that Paxlovid kept him away from the hospital, and stopped his infection from becoming more severe initially. “Paxlovid did what it was supposed to do,” he said in an interview with the outlet.

Paxlovid is a pill approved for treatment of COVID-19 in high-risk adults. It has emergency-use authorization from the U.S. Food and Drug Administration.

Fauci was prescribed Paxlovid owing to his advanced age, which puts him at greater risk for a severe outcome from COVID. He is fully vaccinated and twice boosted, Bloomberg reported.

Earlier this month Pfizer, which manufactures the medication, announced that it would stop adding new participants to a trial of the drug among COVID patients at low risk of hospitalization and death. The study failed to demonstrate that the drug reduced symptoms, or hospitalizations and deaths in a statistically significant way, according to Bloomberg.

The U.S. Centers for Disease Control and Prevention in May issued a health advisory regarding “COVID-19 rebound,” also known as “Paxlovid rebound.” 

But “a brief return of symptoms may be part of the natural history of SARS-CoV-2 (the virus that causes COVID-19) infection in some persons, independent of treatment with Paxlovid and regardless of vaccination status,” the advisory stated.

There is no evidence that additional treatment is needed for rebound cases, the CDC said in the advisory. It is unclear why Fauci took a second course of Paxlovid, in light of this guidance.
Patients who rebound after taking Paxlovid will need to isolate again for five days, according to the CDC. Such patients can report their rebound cases here.

June 29, 2022: This story has been updated to reflect additional comments that Dr. Anthony Fauci made about his Paxlovid treatment

Sign up for the Fortune Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.

About the Author
By Erin Prater
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

school
North AmericaEducation
First and second graders born during their pandemic are worse at math and reading
By Moriah Balingit and The Associated PressMarch 10, 2026
1 day ago
A woman in a red coat holds up a sign that says, “Shouldn’t hurt to be a nurse.”
EconomyLabor
Health care has been propping up a shaky labor market. For the first time in over four years, the sector shed thousands of jobs
By Sasha RogelbergMarch 9, 2026
2 days ago
stitch
Future of WorkSocial Media
‘It feels like a video game, but in real life’: Gen Z’s love of analog ‘grandma’ hobbies jump from Pokemon to bird-watching, scrolling to needlepoint
By Kaitlyn Huamani and The Associated PressMarch 9, 2026
2 days ago
HealthLongevity
From thyroid cancer to 40‑hour fasts: Inside Daymond John’s obsession with biohacking and living longer
By Sydney LakeMarch 8, 2026
3 days ago
AImental health
Chatbots are ‘constantly validating everything’ even when you’re suicidal. New research measures how dangerous AI psychosis really is
By Catherina GioinoMarch 7, 2026
4 days ago
adams
CommentaryVaccines
Trump’s former Surgeon General: voters widely support vaccine access and want Washington to focus elsewhere
By Jerome AdamsMarch 7, 2026
4 days ago

Most Popular

placeholder alt text
Economy
'This cannot be sustainable': The U.S. borrowed $50 billion a week for the past five months, the CBO says
By Eleanor PringleMarch 10, 2026
1 day ago
placeholder alt text
Future of Work
Shark Tank's Kevin O'Leary doesn't care if you work from your basement. He just wants to know if you can ‘execute’
By Marco Quiroz-GutierrezMarch 10, 2026
1 day ago
placeholder alt text
Real Estate
Billionaires Elon Musk and Mark Zuckerberg used mortgages to buy multimillion-dollar mansions. Here’s why that’s a savvy financial decision
By Sydney LakeMarch 9, 2026
2 days ago
placeholder alt text
Big Tech
Big tech has defeated everything for 30 years, but for the first time faces something it can't control: a jury
By Carolina Rossini and The ConversationMarch 10, 2026
19 hours ago
placeholder alt text
Politics
Washington state wants to keep employers from microchipping workers, before anyone even gets the idea
By Catherina GioinoMarch 10, 2026
20 hours ago
placeholder alt text
Economy
Trump's immigration crackdown is backfiring by hurting the U.S.-born workers it was meant to help, data shows
By Sasha RogelbergMarch 10, 2026
21 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.